Effects of linagliptin vs glimepiride stratified by prior insulin secretagogue use in the cardiovascular outcome study of linagliptin versus glimepiride in type 2 diabetes (CAROLINA) trial

被引：0
|
作者：
McGuire, D. K. [1 ]
Rosenstock, J. [2 ]
Johansen, O. E. [3 ]
Zinman, B. J. [4 ]
Khunti, K. [5 ]
Mattheus, M. [6 ]
Lund, S. S. [3 ]
Espeland, M. A. [7 ]
Marx, N. [8 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[2] Dallas Diabet Res Ctr Med City, Dallas, TX USA
[3] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[4] Univ Hlth Network, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Toronto, ON, Canada
[5] Univ Leicester, Leicester, Leics, England
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[7] Wake Forest Univ, Winston Salem, NC 27101 USA
[8] RWTH Univ Hosp Aachen, Aachen, Germany
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3356 / 3356
页数：1
相关论文
共 50 条
  • [31] Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial
    Kraaijenhof, Jordan
    Muskiet, Marcel H. A.
    Tonneijck, Lennart
    Ouwens, D. Margriet
    Kramer, Mark H. H.
    van Raalte, Daniel H.
    Smits, Mark M.
    DIABETES OBESITY & METABOLISM, 2020, 22 (10): : 1847 - 1856
  • [32] Beta cell function in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2 year double-blind randomised controlled study
    Johansen, O.
    Boehm, B.
    Grill, V.
    Torjesen, P. A.
    Bhattacharya, S.
    Patel, S.
    Wetzel, K.
    Woerle, H. -J.
    DIABETOLOGIA, 2012, 55 : S67 - S68
  • [33] Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk The CARMELINA Randomized Clinical Trial
    Rosenstock, Julio
    Perkovic, Vlado
    Johansen, Odd Erik
    Cooper, Mark E.
    Kahn, Steven E.
    Marx, Nikolaus
    Alexander, John H.
    Pencina, Michael
    Toto, Robert D.
    Wanner, Christoph
    Zinman, Bernard
    Woerle, Hans Juergen
    Baanstra, David
    Pfarr, Egon
    Schnaidt, Sven
    Meinicke, Thomas
    George, Jyothis T.
    von Eynatten, Maximilian
    McGuire, Darren K.
    Aizenberg, D.
    Fiorella, A.
    Edgardo, N.
    Belen, C. Ianina
    Alonso, P.
    Walter, M.
    Maia, K.
    Guillermo, S.
    Leandro, B.
    Constanza, R. M.
    Alejandra, N. M.
    Melina, C.
    Ariel, I. L.
    Martin, S.
    Rodrigo, C.
    Alvarez, C.
    Jorge, M. Z.
    Gabriel, C.
    German, S.
    Bartolacci, I.
    Bolobanich, G. A.
    Tale, T.
    Meritano, M.
    Echeverria, M. G.
    Gerrini, S. P.
    Alvarez, M. R. y
    Torrijos, N.
    Berli, M.
    Coggiola, J.
    Castaneda, G.
    Rode, R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (01): : 69 - 79
  • [34] Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus
    Hassan, Memy Hegazy
    Abd-Allah, Gamil Mohamed
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 28 (05) : 1723 - 1730
  • [35] Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial
    Petrica, Ligia
    Petrica, Maxim
    Vlad, Adrian
    Jianu, Catalin Dragos
    Gluhovschi, Gheorghe
    Ianculescu, Calina
    Dumitrascu, Victor
    Giju, Sorin
    Gluhovschi, Cristina
    Bob, Flaviu
    Ursoniu, Sorin
    Gadalean, Florica
    Velciov, Silvia
    Bozdog, Gheorghe
    Marian, Roxana
    WIENER KLINISCHE WOCHENSCHRIFT, 2009, 121 (23-24) : 765 - 775
  • [36] Glimepiride use is associated with reduced cardiovascular mortality in patients with type 2 diabetes and chronic heart failure: a prospective cohort study
    He, Wu
    Yuan, Gang
    Han, Yu
    Yan, Yongcui
    Li, Gen
    Zhao, Chengcheng
    Shen, Jingshan
    Jiang, Xiangrui
    Chen, Chen
    Ni, Li
    Wang, Dao Wen
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 30 (06) : 474 - 487
  • [37] C-Peptide Levels in Latent Autoimmune Diabetes in Adults Treated With Linagliptin Versus Glimepiride: Exploratory Results From a 2-Year Double-Blind, Randomized, Controlled Study
    Johansen, Odd Erik
    Boehm, Bernhard O.
    Grill, Valdemar
    Torjesen, Peter A.
    Bhattacharya, Sudipta
    Patel, Sanjay
    Wetzel, Kristiane
    Woerle, Hans-Juergen
    DIABETES CARE, 2014, 37 (01) : E11 - E12
  • [38] Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
    Wanner, Christoph
    Cooper, Mark E.
    Johansen, Odd Erik
    Toto, Robert
    Rosenstock, Julio
    McGuire, Darren K.
    Kahn, Steven E.
    Pfarr, Egon
    Schnaidt, Sven
    von Eynatten, Maximilian
    George, Jyothis T.
    Gollop, Nicholas D.
    Marx, Nikolaus
    Alexander, John H.
    Zinman, Bernard
    Perkovic, Vlado
    CLINICAL KIDNEY JOURNAL, 2021, 14 (01) : 226 - 236
  • [39] Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes A retrospective cohort study
    Chin, Hyouk-Jun
    Nam, Jin Hyun
    Lee, Eui-Kyung
    Shin, Ju-Young
    MEDICINE, 2017, 96 (25)
  • [40] Neuro- and renoprotective effects of pioglitazone versus glimepiride in normoalbuminuric patients with type-2 diabetes mellitus: a randomized controlled trial
    Petrica, M.
    Petrica, L.
    Vlad, A.
    Jianu, D. C.
    Gluhovschi, G.
    Ianculescu, C.
    Firescu, C.
    Dumitrascu, V.
    Gadalean, F.
    Giju, S.
    Gluhovschi, C.
    Ursoniu, S.
    Velciov, S.
    Milas, O.
    Balgradean, C.
    Gaina, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 493 - 493
12345